Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Brain Functional Genome Program

Major cross-functional Brain Functional Genome Program (BFGP)

Last update: 17/01/2025 Reading time: 1min

Deepen our understanding of the human brain during development 

The context

The BFGP program aims to tackle the following key questions:  

  • What are the molecular signatures of human brain cells across age in health and disease?
  • What are the functions of key genes in brain development, function and disease? 
The project's goals

The project's goals

The main goal of the program is to deepen our understanding of the human brain during development by linking gene expression locations to their functions, by providing to the wide community focusing in neurological and neurodegenerative diseases established, robust techniques and characterized tools.

Aim1: Atlas of the human and mouse brain molecular signature in development

We will leverage our expertise in state-of the art technologies to perform 3D visualization(iDISCO) of transcripts, combined with spatial transcriptomics on the human fetal brain, and mouse brain in development. We will develop strategies for large samples imaging, with the goal not only to develop an atlas of the human brain but also to provide a complete pipeline from protocol to analysis to the community. 


Aim2: Functional screening of disease-causing genetic variants in neurogenesis

The goal is to build an IPSC library of characterized clones. We will build a guide-RNA library for the whole genome through gene silencing (CRISPR interference). This library will serve to generate individual IPS cell lines that will be screened in 2D. More complex models, such as organoids, will be used in a later phase of the program.


Aim3: Machine learning assisted quantification of cell types 

Establish connections between the datasets (Aims 1 and 2) using ML 

News that might interest you

À la recherche de marqueurs d’imagerie dans la démence frontotemporale
Searching for Imaging Markers in Frontotemporal Dementia
Could exploring the relationships between different brain networks help us understand frontotemporal dementia (FTD)? This neurodegenerative disease, which progresses at varying rates, is often diagnosed late—when clinical signs are already severe. At...
01.07.2025 Research, science & health
Monocyte – un globule blanc qui se différencie en macrophage. Crédit : Université d’Edinbourg.
Discovery of a Macrophage Anomaly in Multiple Sclerosis
Certain patients with multiple sclerosis (MS) can partially regenerate myelin—the protective sheath that surrounds nerve fibers—which is damaged during the evolution of the disease. In studying how immune cells influence this remyelination...
12.19.2024 Research, science & health
Interneurones. Crédit : UCLA Broad Stem Cell Research Center.
Stimulating specific neurons in the striatum stops compulsive behaviour
What if we could resist compulsions? These irrational behaviours, particularly common in obsessive-compulsive disorder (OCD), are hard to suppress. At Paris Brain Institute, Éric Burguière's team shows that we can anticipate them and block them...
09.10.2024 Research, science & health
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.
Ultrasound show unexpected effects on motor neuron disease
Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain...
09.05.2024 Research, science & health
Un neurone
Rett syndrome: a new gene therapy on the way
Gene therapy could be our best chance of treating Rett syndrome, a neurological disorder that causes severe intellectual and motor impairments. At Paris Brain Institute, Françoise Piguet and her colleagues have looked closely at brain cholesterol...
07.16.2024 Research, science & health
Lésions d’un patient à l’inclusion dans le protocole (M0) disparues après 2 ans de traitement à la Leriglitazone (M24)
The dual effect of leriglitazone in X-linked Adrenoleukodystrophy (X-ALD)
In 2023, the team led by Professor Fanny Mochel (AP-HP, Sorbonne University), a Paris brain Institute researcher, showed that daily dose of leriglitazone slow down the progression of myelopathy in patients with X-linked adrenoleukodystrophy, and...
06.28.2024 Research, science & health
See all our news